The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic
development for Dementia and features dormant and discontinued projects. The guide covers therapeutics
under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase
III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 19, 1, 39, 10 and 3
respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11
and 3 molecules, respectively.
Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities and helps to create effective counter
strategies to gain competitive advantage. The guide is built using data and information sourced from
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party
sources. Additionally, various dynamic tracking processes ensure that the most recent developments are
captured on a real-time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and
relevance of data.
Request A Sample copy of This Report @
https://www.hexareports.com/report/dementia-pipeline-review-h2-2017/request-sample
Scope
•
•
•
•
•
•
•
•
The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central
Nervous System).
The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies
and universities/research institutes based on information derived from company and industry-specific
sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-
registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product
description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental
activities.
The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics
and enlists all their major and minor projects.
The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of
action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous
System)
Follow Us: